
    
      A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of
      AZD5213 and Placebo in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment
      During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel
      Group, Placebo-Controlled Study
    
  